# A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

> **NCT04295005** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24500 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** DPP-4i
- **DRUG:** GLP-1-RA

## Key facts

- **NCT ID:** NCT04295005
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-16
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 24500 (ACTUAL)
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04295005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04295005, "A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04295005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*